Sunitinib for Cancer

Recruiting in Palo Alto (17 mi)

Overseen byLilian T Gien

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: National Cancer Institute (NCI)

No Placebo Group

Prior Safety Data

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?This phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the cKIT gene. It works by blocking the action of mutated cKIT that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Eligibility Criteria

This trial is for cancer patients with a specific genetic change in the cKIT gene. It's open to those with lymphoma, multiple myeloma, or solid tumors who meet certain health standards. People are excluded if they don't have the cKIT mutation or if their health conditions make it unsafe to participate.

Inclusion Criteria

Total bilirubin must be within normal institutional limits

My kidney function is normal or meets the required levels for the study.

Patients must fulfill all eligibility criteria of MATCH Master Protocol at the time of registration to treatment step (Step 1, 3, 5, 7)

+6 more

Exclusion Criteria

My thyroid condition cannot be controlled with medication.

I haven't had any major abdominal issues like a fistula, perforation, or abscess in the last 28 days.

I am allergic or had a bad reaction to sunitinib or similar drugs.

+13 more

Participant Groups

The trial is testing Sunitinib, a kinase inhibitor medication that targets cancers with cKIT mutations. Patients will undergo various assessments including biopsies and imaging tests like MRI and CT scans to see how well the treatment works.

1Treatment groups

Experimental Treatment

Group I: Treatment (sunitinib)Experimental Treatment7 Interventions

Patients receive sunitinib 50 mg PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.

Sunitinib is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸 Approved in United States as Sutent for: